KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Inventory (2017 - 2025)

Historic Inventory for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $7.0 million.

  • Bionano Genomics' Inventory fell 5078.54% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 5078.54%. This contributed to the annual value of $11.1 million for FY2024, which is 5141.97% down from last year.
  • Per Bionano Genomics' latest filing, its Inventory stood at $7.0 million for Q3 2025, which was down 5078.54% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Inventory registered a high of $33.1 million during Q1 2023, and its lowest value of $3.0 million during Q1 2021.
  • In the last 5 years, Bionano Genomics' Inventory had a median value of $16.3 million in 2022 and averaged $17.1 million.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 43583.66% in 2022, then plummeted by 5567.14% in 2025.
  • Bionano Genomics' Inventory (Quarter) stood at $12.4 million in 2021, then skyrocketed by 140.26% to $29.8 million in 2022, then decreased by 23.08% to $22.9 million in 2023, then crashed by 51.42% to $11.1 million in 2024, then tumbled by 36.62% to $7.0 million in 2025.
  • Its Inventory was $7.0 million in Q3 2025, compared to $8.6 million in Q2 2025 and $9.6 million in Q1 2025.